Reaktionsgleichung
[N:1]1([CH2:7][C:8]2([C:14]3[CH:19]=[CH:18][C:17]([OH:20])=[CH:16][CH:15]=3)[CH2:13][CH2:12][O:11][CH2:10][CH2:9]2)[CH2:6][CH2:5][O:4][CH2:3][CH2:2]1.[CH:21]([N:24]1[CH2:29][CH2:28][CH:27](O)[CH2:26][CH2:25]1)([CH3:23])[CH3:22].C1C=CC(P(C2C=CC=CC=2)C2C=CC=CC=2)=CC=1.CC(OC(/N=N/C(OC(C)C)=O)=O)C>>[CH:21]([N:24]1[CH2:29][CH2:28][CH:27]([O:20][C:17]2[CH:16]=[CH:15][C:14]([C:8]3([CH2:7][N:1]4[CH2:2][CH2:3][O:4][CH2:5][CH2:6]4)[CH2:13][CH2:12][O:11][CH2:10][CH2:9]3)=[CH:19][CH:18]=2)[CH2:26][CH2:25]1)([CH3:23])[CH3:22]Komponenten
5
Versuchsvorschrift
The title compound (52 mg, 12%) was prepared using 4-[4-(morpholin-4-ylmethyl)tetrahydro-2H-pyran-4-yl]phenol, 1-isopropyl-4-hydroxypiperidine (step 1 of intermediate 21), PPh3 and DIAD similarly to the procedure used for intermediate 55. 1H NMR (400 MHz, CD3OD) δ 1.09 (d, 6H), 1.74-1.80 (m, 2H), 1.83-1.90 (m, 2H), 1.98-2.04 (m, 2H), 2.12-2.18 (m, 6H), 2.40 (s, 2H), 2.47 (t, 2H), 2.75 (m, 1H), 2.80-2.85 (m, 2H), 3.47-3.54 (m, 6H), 3.71-3.77 (m, 2H), 4.36 (m, 1H), 6.90 (d, 2H), 7.28 (d, 2H). HRMS ESI+ m/z 403.2951 [MH]+.
Quellen und Nachweise
- ORD-Eintrag
- ord-913d5c1d9b8943f7a6b6582bb1cc9706
- Quelldatensatz
- uspto-grants-2008_11
- Patentnummer
- US07456164B2
Verknüpfte Notizen
Wird geladen…